MSB Trading - 2020, page-3806

@justcurious So you don't remember? It wasn't directed at you so why would remember that?

You slipped in some doubt ...how skilled of you.

The statement is quite self-explanatory. But you don't understand it? And you think others don't either.

We ALL know we're talking about stem cells at the higher end. Right?

Now what would be the lower end?...think now.

It would be when cells are differentiated into for instance, lung cells, or skin cells. Or lower down the biological chain/hierachy which is where drug treatment happens, as Silvio Itescu referred to it. Is that really hard?

DNA complexities would be at the lower end. Got it? Because I did, immediately.

That's the point of an analogy, to communicate clearly and simply.

So you need a bigger patient cohort to show patient safety with drugs, to have more variety in the DNA spread. Which is more expensive. So naturally this resulted in what some of us were expecting: patient safety is not the issue as much with stem cells as drugs so we got much smaller cohorts.

So you admire @hottuna? OK.